Many thanks to Roche for joining BioFIT 2021 as a Bronze Sponsor

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to invest heavily in research and development with CHF 11 billion in 2018. Alongside the broad internal pipeline, external innovation has always been a critical component of the Roche research and development strategy.

Join key BioFIT 2021 sponsors such as Boehringer Ingelheim, Genfit, MSD, Roche and Novo Nordisk to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Many thanks to MSD for joining BioFIT 2021 as a Silver Sponsor

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs.  Our scientific advances have made a difference in the lives of millions of patients worldwide… and many of these advances were the result of partnerships.  In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality.  We believe that by working together we can play a major role in transforming global health care.  Together we can invent for life.

Join key BioFIT 2021 sponsors such as Boehringer Ingelheim, Genfit, MSD and Novo Nordisk to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Many thanks to Genfit for joining BioFIT 2021 as a Bronze Sponsor

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor* in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp® in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. Nasdaq and Euronext: GNFT.
* Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority

Join key BioFIT 2021 sponsors such as Boehringer Ingelheim and Genfit to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

NEW DATES & FORMAT:
December 7th – 9th, 2021 | Digital event

Dear Community,
 
Guided by a concern for everyone’s health, BioFIT organisers and its Steering Committee have come to the conclusion that the best option for the upcoming edition of BioFIT was to move forward with a digital format and to extend it to 3 days.
 
The next edition of BioFIT, initially scheduled to take place in December 2021 in Strasbourg, will therefore be held ONLINE, from December 7th to 9th, 2021.
 
Given the evolution of the health situation, it seems safer to hold an international event like BioFIT in a 100% digital format this year again.
Indeed, while we are aware that we could expect a return to normal after the summer with vaccination, the uncertainties we are currently still facing regarding sanitary measures and international business travel for the end of the year significantly compromise a proper promotion for our event in a physical format.
 
Holding the next edition of BioFIT digitally, and announcing it now, will make it easier for our ecosystem to plan their participation in the event and ensure that a critical mass is reached for the 2021 edition.
 
We are convinced that holding the event in a digital format will be beneficial both in terms of quality and attendance.
Going online will allow us to fulfil our promise: to bring satisfaction to our participants and our partners in terms of meeting opportunities, deals achieved, partnerships launched…
Moreover, in order to enable more meeting opportunities and avoid “zoom-fatigue”, the duration of the event is extended to 3 days rather than 2.

Our choice has been to resort to a high-quality digital solution to offer you an optimal user experience. 
With the same top-notch one-on-one partnering meetings, valuable content and high-level experts, BioFIT Digital continues to safely offer you a unique experience, and to help you drive innovation forward in the sector.

The registration and exhibition fees to the event have been adjusted.

Register now and benefit from the Super Early Bird offer valid until April 29th, 2021!

You can count on our commitment to deliver the upcoming edition of BioFIT in the best conditions and to guide you through this digital configuration.
Please stay tuned for more information on the format, and do not hesitate to contact us if you have any questions.

We look forward to seeing you virtually in December!
Best regards,
The BioFIT team

Many thanks to Boehringer Ingelheim for joining BioFIT 2021 as a Bronze Sponsor

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. 

Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of 17.5 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 18.1 per cent of net sales. 

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. 

Join key BioFIT 2021 sponsors such as Boehringer Ingelheim and Genfit to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Discover the BioFIT 2021 brand new brochure!

Donwload it to learn more about the 10th edition of BioFIT,
the leading European
partnering event for earlystage deals and investment rounds in the Life Sciences field!

A successful 2020 edition

For this 9th edition, BioFIT, the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field, was organised for the first time in a digital format and was a real success.

This digital experience over 4 days has allowed participants to take away new ideas, new collaborations and new funding opportunities from their participation, all to build the innovations of tomorrow in the Life Science industry.

Over 1,000 attendees from over 36 countries have attended BioFIT/MedFIT Digital 2020. During the 4 day-event, 9,000 one-to-one meetings have been generated, 70 speakers have debated the right funding sources for early-stage innovation, the best practices in academia-industry R&D collaborations, and the winning ways to nurture emerging assets, 70 entities have increased their visibility through exhibition virtual stands, and 62 innovative projects previously selected have had the opportunity to pitch.

Save the date for the 10th edition

We hope to get the pleasure to welcome you to the next edition of BioFIT, in the charming city of Strasbourg, on December 14th and 15th, 2021. Looking forward to seeing you!

Register now and benefit from the Super Early Bird offer valid until March 31st, 2021!

StemSight, elected as the most innovative start-up

Among 35 applications received, 13 start-ups were selected to pitch during the Start-up Slams at BioFIT in different categories such as oncology, ophthalmology, cell therapy, infection, parasitic, inflammation, cardio-metabolic, gastrointestinal and tools (research, delivery, clinical development). StemSight, a Finnish start-up involved in Ophthalmology and Cell Therapy, represented by Laura Koivusalo, Founder and CEO, is the winner of this year’s edition of the Start-up Slams:

We are honoured to be considered as the most innovative start-up by the high-level jury of BioFIT, even though we are still in the very early stages. It is especially valuable to gain feedback on not just the pitching but also on the technology and business considerations of the project. This recognition from the BioFIT jury will hopefully also give an additionally boost to our fundraising.”

StemSight is developing new treatments for blindness by differentiating cell therapies from human pluripotent stem cells. StemSight is initially targeting a rare form of corneal blindness called limbal stem cell deficiency, a state where the cells responsible for the normal healing of the ocular surface are lost to injury or disease. StemSight’s approach aims to cure limbal stem cell deficiency permanently, by implanting allogeneic pluripotent stem cell-derived limbal stem cells to the corneal surface. StemSight is currently in the process of spinning out from Tampere University in Finland and raising their seed funding.

Antikor Biopharma Ltd., elected as the most promising technology

20 TTOs, universities, research institutes and companies applied to the BioFIT Collaborative and Licensing Opportunity Presentations to showcase their technology in front of potential partners in order to entail a collaborative project and / or a licensing deal. 8 of them have been selected to pitch during BioFIT in 3 different categories: infection/parasitic, oncology, tools/diagnostic. Antikor Biopharma Ltd., a British project involved in Oncology, represented by Dr. Mahendra Deonarain, Chief Executive and Science Officer, received the “Most Promising Technology” award:

This was our first attendance at BioFIT and were impressed by the organisation and breadth of attendees. We were pleased to have been selected to give a partnering presentation and even more honoured to be selected as a winner for the best technology pitch. The judges feedback was very detailed and knowledgeable and their understanding of our value proposition and choice for the award validates our approach. We are indeed grateful for this recognition. Our progress in a difficult 2020 has been due to the exceptional team at Antikor and we hope that 2021 will be our most successful year yet.”

Antikor, based in Stevenage, UK are innovators in ADCs (Antibody-Drug Conjugates). After many years of disappointment and failures, the ADC area has recently resurged, doubling the number of product approvals in the last 2 years. However, despite this renewed optimism, treating difficult solid tumours like gastric, pancreatic and lung remain a significant challenge which is where Antikor’s Fragment Drug Conjugate (FDC) technology fits. FDCs uses smaller antibody formats, optimised for superior tumour penetration, but systemically clear more rapidly providing reduced normal tissue exposure. Using carefully chosen, stable human frameworks, highly tolerable to bioconjugation, Antikor’s FDCs obtain higher payload loading ratios making them more potent. These features leads to benefits of improved efficacy and superior tolerability leading to a larger therapeutic window for treating solid tumours. Antikor has a strong platform for FDC discovery, an integrated R&D team to develop innovative products, backed by strong IP. Antikor’s two lead programmes are at the advanced pre-clinical stage: ANT-43 (breast and gastric cancer) is partnered with Hong Kong-listed Pharma company, Essex Biotechnology and our new flagship programme, ANT-45 is for gastric, lung and colon cancer. Antikor attended BioFIT 2020 to introduce its technology and products and to initiate partnership discussions for ANT-45.

PRONOZIA, elected as the most innovative animal health project

3 innovative animal health projects have been selected among companies that applied to the Animal Health Presentations and showcased their project in front of potential partners and investors. PRONOZIA, a French project involved in Animal Health, represented by Olivier Denis, President and Founder, is the winner of this year’s edition of the Animal Health Presentations:

We are very proud that “ZAG concept by PRONOZIA” wins the 2020 award of the “most innovative animal health project” presented by SIMV/BioFIT. Winning this award in a highly competition line-up, it is a great recognition of huge work accomplished and a great satisfaction for PRONOZIA team and partners. “ZAG concept” is a new generation decision support tool at the service of vet professionals, based on data science and data management. Thanks to SIMV and BioFIT for organising these pitching sessions which are very interesting opportunities to share with investors and partners the outcome of 3 years of R&D work.”

PRONOZIA is a company specialised in digital technologies applied to the animal health field. PRONOZIA develop innovative custom digital tools and services for animal healthcare professional, based on data science and data management methodologies using a combination of algorithmic mathematics, statistical models and machine learning. PRONOZIA finalises the development of “ZAG concept”, a decision support platform. “ZAG concept” provides qualified scientific data for helping vet practitioners to improve management of their daily clinical cases.

2020 is the third year in a row that Belgium has ranked as the best biotech country in Europe!
To keep up to date on this fantastic life sciences ecosystem, follow our media partner @BioVox via their newsletter or on Twitter & LinkedIn!